CJC-1295 + Ipamorelin Stack

GH secretion is blunted by hyperglycemia and elevated free fatty acids. Injections within 2 hours of carbohydrate-rich meals produce smaller GH pulses, muting the intended effect.

DAC (Drug Affinity Complex) extends CJC-1295's half-life to ~8 days by binding albumin, creating a sustained GH elevation rather than discrete pulses. No-DAC CJC-1295 (also called Mod GRF 1-29) has a ~30-minute half-life, producing sharp pulses that mimic natural GH secretion patterns. No-DAC is preferred because pulsatile GH release maintains receptor sensitivity and produces a more physiological hormonal profile.

The primary objective marker is IGF-1 levels — test at baseline and 4–6 weeks into the protocol. A 20–50% increase in IGF-1 within the age-adjusted reference range confirms pituitary response. Subjective markers include improved sleep quality (deeper sleep, more vivid dreams), faster recovery from training, and improved skin quality. Body composition changes (fat loss, modest lean mass gain) take 8–12 weeks to become measurable.

Most protocols cycle 8–12 weeks on, 4–8 weeks off. The cycling rationale is to prevent pituitary desensitization and keep IGF-1 within safe ranges. Some practitioners run lower-dose protocols for longer periods with regular IGF-1 monitoring. Indefinite use at full dose without breaks is not recommended due to insufficient long-term safety data and theoretical concerns about sustained IGF-1 elevation.

The most common are water retention (puffy fingers, tight rings), joint stiffness, and tingling or numbness in the hands (carpal tunnel-like symptoms from fluid shifts). These indicate the GH effect is working but may be excessive — dose reduction usually resolves them. Elevated fasting glucose suggests GH-mediated insulin resistance and warrants immediate attention. All of these should be discussed with a supervising clinician.

Pre-bed injection on an empty stomach (2+ hours after your last meal) is the most widely recommended timing. This aligns with the body's natural GH secretion pattern, which peaks during the first cycle of slow-wave sleep. The fasted state is critical because elevated blood glucose and insulin suppress GH release, significantly blunting the peptide effect. Some practitioners add a second injection upon waking (also fasted) for enhanced results, but the bedtime dose alone captures the largest natural GH pulse window. Avoid injecting within 30 minutes of eating or consuming anything caloric.

Growth hormone increases the peripheral conversion of T4 to T3 (the active thyroid hormone) by upregulating deiodinase enzymes. In individuals with adequate thyroid reserve, this may slightly increase free T3 levels. However, in individuals with borderline or subclinical hypothyroidism, GH stimulation can unmask thyroid insufficiency by increasing T4-to-T3 conversion demand beyond what the gland can supply, leading to a drop in T4 and symptoms of hypothyroidism. Thyroid panel testing (TSH, free T3, free T4) at baseline and 6–8 weeks into a GH peptide cycle is recommended, especially for those with a history of thyroid issues.

Injectable HGH (somatropin) delivers exogenous growth hormone directly, bypassing the pituitary entirely. GH peptides (CJC-1295/Ipamorelin) stimulate your own pituitary to produce and release GH in physiological pulses. The key differences: HGH produces supraphysiological, non-pulsatile GH levels that can suppress your pituitary's natural function over time; GH peptides produce pulsatile release that maintains feedback regulation. HGH is more potent and predictable but carries higher risk of side effects, pituitary suppression, and is significantly more expensive. GH peptides are gentler, preserve natural regulation, but produce more modest GH elevations. For anti-aging and general wellness, GH peptides are generally preferred; for severe GH deficiency, pharmaceutical HGH is the clinical standard.

Women can use CJC-1295/Ipamorelin at the same doses as men, though there are important physiological differences to consider. Women naturally produce GH in a more frequent, lower-amplitude pulsatile pattern compared to men's less frequent, higher-amplitude pulses. Estrogen increases GH secretion but induces hepatic GH resistance, meaning women may have higher GH levels but lower IGF-1 responses per unit of GH. Practically, this means women may see a smaller IGF-1 increase at equivalent doses and may need adjusted expectations for lab results. Women on oral estrogen (HRT or contraceptives) will have further attenuated IGF-1 response. Monitoring IGF-1 is equally important for both sexes, and dose adjustments should be guided by lab results rather than gender-based assumptions.